Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir , approved by the European Commission under the tradename Sovaldi in January 2014.